X0306 4 2019-12-09 0 0001740547 Urovant Sciences Ltd. UROV 0001314596 Katkin Keith C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617 1 1 0 0 PEO;CEO/Urovant Sciences, Inc. Common Shares 2019-12-09 4 M 0 120000 3.86 A 120000 D Common Shares 2019-12-09 4 S 0 120000 12.78 D 0 D Stock Option (Right to Buy) 3.86 2019-12-09 4 M 0 120000 0.00 D 2027-09-21 Common Shares 120000 881254 D This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.35 to $12.885. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed to minimize the potential impact of 280G excise tax, which may be triggered by the change of control resulting from the acquisition by Sumitomo Dainippon Pharma Co., Ltd. of Roivant Sciences Ltd.'s ownership interest in the Issuer. Following the reported transaction, the Reporting Person beneficially owns options to purchase an aggregate of 1,596,166 common shares. 25% of the total shares underlying the option vested and became exercisable on September 21, 2018; the remaining shares vest in 12 equal quarterly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. /s/ Bryan Smith, Attorney-in-Fact 2019-12-11